BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37057215)

  • 21. Pituitary imaging is indicated for the evaluation of hyperprolactinemia.
    Bayrak A; Saadat P; Mor E; Chong L; Paulson RJ; Sokol RZ
    Fertil Steril; 2005 Jul; 84(1):181-5. PubMed ID: 16009175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?
    Bahceci M; Tuzcu A; Bahceci S; Tuzcu S
    J Endocrinol Invest; 2003 Jul; 26(7):655-9. PubMed ID: 14594118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
    Robin G; Catteau-Jonard S; Young J; Dewailly D
    Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic evaluation of hyperprolactinemia.
    Biller BM
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of Macroprolactin in Hyperprolactinemia.
    Sherazi NA; Baig MZ; Khan AH
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):93-97. PubMed ID: 29394965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital.
    Saejong R; Dangrat C; Techatrisak K; Angsuwatthana S; Rattanachaiyanont M; Tanmahasamut P
    J Med Assoc Thai; 2013 Oct; 96(10):1247-56. PubMed ID: 24350404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. True hyperprolactinemia in men without visible pituitary adenoma.
    Shimon I; Rudman Y; Manisterski Y; Gorshtein A; Masri H; Duskin-Bitan H
    Endocrine; 2021 Jun; 72(3):809-813. PubMed ID: 33566310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperprolactinemia after laparoscopic ovarian drilling: an unknown phenomenon.
    Parsanezhad ME; Alborzi S; Zolghadri J; Parsa-Nezhad M; Keshavarzi G; Omrani GR; Schmidt EH
    Reprod Biol Endocrinol; 2005 Aug; 3():31. PubMed ID: 16083511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
    De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
    Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperprolactinemia].
    König MP; Kopp P
    Schweiz Med Wochenschr; 1986 Mar; 116(9):265-70. PubMed ID: 3952483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
    Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
    Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The detection of macroprolactin by precipitation and ultrafiltration methods.
    Beda-Maluga K; Pisarek H; Komorowski J; Pawlikowski M; Świętosławski J; Winczyk K
    Endokrynol Pol; 2011; 62(6):529-36. PubMed ID: 22144220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome].
    Wang Y; Hu ZP; Li MZ; Li R; Wang LN; Chen XN; Yang CS; Qiao J
    Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2599-603. PubMed ID: 20137674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
    Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Oku Y; Onishi T; Uozumi T
    No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
    Sahmay S; Atakul N; Aydogan B; Aydin Y; Imamoglu M; Seyisoglu H
    Acta Obstet Gynecol Scand; 2013 Dec; 92(12):1369-74. PubMed ID: 23980726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
    Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
    Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
    Varaldo E; Cuboni D; Prencipe N; Aversa LS; Sibilla M; Bioletto F; Berton AM; Gasco V; Ghigo E; Grottoli S
    Endocrine; 2024 May; 84(2):670-676. PubMed ID: 38194218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprolactinemia and associated pituitary prolactinomas.
    Brenner SH; Lessing JB; Quagliarello J; Weiss G
    Obstet Gynecol; 1985 May; 65(5):661-4. PubMed ID: 4039046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.